Literature DB >> 7351582

Depressed serum somatomedin activity in beta-thalassemia.

P Saenger, E Schwartz, A L Markenson, J H Graziano, L S Levine, M I New, M W Hilgartner.   

Abstract

We have found bioassayable somatomedin activity to be subnormal in 20 of 32 children and adults with beta-thalassemia. The levels were comparable to values reported in growth hormone-deficient subjects. Since patients with thalassemia are not growth hormone deficient, the data suggest the possibility of defective hepatic biosynthesis of somatomedin. Increased iron stores in these patients, who have secondary hemosiderosis of many organs, including the liver, may depress somatomedin activity. Therapy for one year with daily subcutaneous infusions of the iron-chelating agent deferoxamine had no effect on mean bioassayable serum somatomedin activity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351582     DOI: 10.1016/s0022-3476(80)80805-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

Review 1.  Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. II: Deleterious consequences.

Authors:  T D Miale; S Sirithorn; S Ahmed
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

2.  Physical growth parameters in thalassemic children.

Authors:  A George; A Bhaduri; S Sen; V P Choudhry
Journal:  Indian J Pediatr       Date:  1997 Nov-Dec       Impact factor: 1.967

Review 3.  Stunted growth with more or less normal appearance.

Authors:  J R Bierich; H Enders; U Heinrich; R Huenges; M B Ranke; D Schoenberg
Journal:  Eur J Pediatr       Date:  1982-12       Impact factor: 3.183

4.  Nutritional factors and thalassaemia major.

Authors:  G J Fuchs; P Tienboon; S Linpisarn; S Nimsakul; P Leelapat; S Tovanabutra; V Tubtong; M DeWier; R M Suskind
Journal:  Arch Dis Child       Date:  1996-03       Impact factor: 3.791

Review 5.  Growth and endocrine function in thalassemia major in childhood and adolescence.

Authors:  M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2010-01       Impact factor: 4.256

6.  Growth hormone response following growth hormone releasing hormone injection in thalassemia major: influence of pubertal development.

Authors:  B P Leheup; M Cisternino; M Bozzola; B Dousset; P L Marradi; F Antoniazzi; L Tato; F Severi; D Sommelet; M Pierson
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

7.  Intrauterine growth retardation. A report of two cases with bird-headed appearance, skeletal changes and peripheral GH resistance.

Authors:  B Boscherini; G Iannaccone; C La Cauza; G Mancuso; F Girotti; G Finocchi; A M Pasquino
Journal:  Eur J Pediatr       Date:  1981-10       Impact factor: 3.183

8.  Evaluation of growth hormone in thalassaemic boys with failed puberty: spontaneous versus provocative test.

Authors:  R Chatterjee; M Katz; T Cox; H Bantock
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

9.  Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major.

Authors:  R G Grundy; K A Woods; M O Savage; J P Evans
Journal:  Arch Dis Child       Date:  1994-08       Impact factor: 3.791

10.  Effects of deferoximine on chondrocyte alkaline phosphatase activity: proxidant role of deferoximine in thalassemia.

Authors:  M Hatori; J Sparkman; C C Teixeira; M Grynpas; J Nervina; N Olivieri; I M Shapiro
Journal:  Calcif Tissue Int       Date:  1995-09       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.